ICLE 2022 | Addressing issues with T-cell therapies for hematologic malignancies
Michela Consonni, PhD, San Raffaele Scientific Institute, Millan, Italy, provides an overview of the key remaining challenges associated with the development of T-cell immunotherapies for hematological disorders. Off-target toxicity remain a major limitation for chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies and targeting antigen escape is especially difficult in anti-CD19-CAR T-cell therapies for B acute lymphoblastic leukemia (B-ALL). Dr Consonni also emphasizes the need to expand the availability of TCR therapies as well as strategies to mitigate the risk of graft versus host disease (GvHD) in patients receiving hematopoietic stem cell transplantation (HSCT). This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
